RegHyal-01Implantes de Ácido Hialurónico para la Apariencia de la Piel Facial en Mujeres Adultas

Fecha de inicio: 30 de marzo de 2021

Inclusion Criteria: * Subject agreed to participate in the Investigation and signed the Informed Consent Form. * Age over 18 years. * The subject is eager to undergo a course of skin redermalization procedures using the medical device(devices) based on non-cross-linked hyaluronic acid in concentrations of 0.55% ("Electri") and 1.1%, 1.8% or 2.2% ("XELA REDERM") (Diaco Biofarmaceutici S. r. l., Italy) in Poland; in concentrations of 1.1%, 1.8% or 2.2% ("XELA REDERM") (Diaco Biofarmaceutici S. r. l., Italy) in Ukraine. * Female subject confirm that she is not pregnant or lactating during the study. Exclusion Criteria: * Infection or inflammation in the implant injection site. * Pregnancy, lactation. * Subject's intention to undergo procedures involving chemical peels, laser irradiation, botulinum toxin injection or other similar procedures in the injection site within the next 45 days after inclusion in the post-marketing investigation. * Subject underwent procedures involving chemical peels, laser irradiation, botulinum toxin injection or other similar procedures in the injection site within 35 days prior to inclusion in the post-marketing investigation. * Chronic or acute severe or decompensated visceral diseases. * Known hypersensitivity to hyaluronic acid, its metabolites, or to the excipients of the injectable implant. * Known hypersensitivity to analgesics. * Subject took significant doses of vitamin E, NSAIDs or anticoagulants during the last 7 days. * Refusal or suspected inability of the subject to comply with the requirements of the CIP. * Subject has difficulty in understanding the language in which the informed consent is written. * Any other reason that, in the opinion of the investigator, prevents the subject from participating in the post-marketing investigation. * Subject takes participation in other clinical investigation.